Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud University Medical Center, Nijmegen, Netherlands) to discuss the ALIFE 2 clinical trial and the impact the findings have for women with inherited thrombophilia.
The abstract entitled ‘Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial’ (Abstract #LB-5) was presented at ASH Annual Meeting, 10–13, December, 2022.
- What was known about the use of anticoagulants to reduce adverse pregnancy outcomes in women with inherited thrombophilia? (0:18)
- What were the aims, design and eligibility criteria of the ALIFE 2 clinical trial? (2:04)
- What were the primary and secondary outcome measures and how well were they achieved in the two groups? (2:45)
- On the basis of these findings, what advice would you give to women with confirmed inherited thrombophilia, with recurrent pregnancy loss? (4:17)
- What further research is needed? (5:41)
Disclosures: Saskia Middeldorp is on the advisory board and has received honoraria from Aspen, Pfizer and Viatris. She has received grant/research support from Aspen and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed as a highlight of ASH 2022
Access more content on Haematology
Share this Video
Related Videos In Haematology
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current […]
Bernd Jilma, ASH 2022: Pegcetacoplan in patients with cold agglutinin disease, the CASCADE phase III trial
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial and when results should be expected. The abstract entitled ‘Trial in Progress: Randomized, Double-Blind, Placebo-Controlled […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!